NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT03304639 2025-11-12
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03599713 2025-08-05
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
Phase 2 Completed
NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03853317 2024-08-09
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
ImmunityBio, Inc.
Phase 2 Terminated
NCT02465957 2024-05-02
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
ImmunityBio, Inc.
Phase 2 Terminated
NCT02155647 2024-03-13
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
Phase 2 Completed
NCT02267603 2023-07-05
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01440816 2023-05-15
MCC
OncoSec Medical Incorporated
Phase 2 Completed
NCT02036476 2023-05-09
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03988647 2021-08-09
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Stanford University
Phase 2 Terminated